关于先锋
Company Profile
12
2023-07
Bioequivalence Study of Sildenafil Citrate Orally Disintegrating Tablets in Human
For the treatment of erectile dysfunction
2023-07-12
12
2023-07
Bioequivalence Study of Fenofibrate Capsules in Human
For adult use It is used for the treatment of hypercholesterolemia (type IIa), endogenous hypertriglyceridemia, simple type (type IV) and mixed type (type IIb and type III) in adults whose diet control therapy is not satisfactory. Especially when the blood cholesterol continues to rise after diet control, or when there are other concurrent risk factors. You should continue to control your diet while taking the medicine. At present, there is no long-term controlled clinical study to prove the effectiveness of fenofibrate in the primary and secondary prevention of atherosclerotic complications. Fenofibrate has not been shown to reduce coronary morbidity and mortality in patients with type 2 diabetes.
2023-07-12
12
2023-07
Bioequivalence Study of Orlistat Capsules in Human
For the treatment of overweight (body mass index ≥ 24) adults 18 years of age and older. When using this product, it should be combined with a low-calorie and low-fat diet
2023-07-12
10
2023-07
The drug marketing license holder (MAH) can produce or commission the production of drugs on their own. MAH commissioned production requires obtaining a drug production license B. The CIO assists MAH in evaluating the entrusted production enterprise, signing the commission agreement and quality agreement, and obtaining the drug production license B.
2023-07-10
10
2023-07
10
2023-07
10
2023-07
10
2023-07
10
2023-07
To all drug dealers and drug users: The "Measures for the Administration of Drug Recall" stipulates that drug manufacturers should regularly initiate simulated recalls to test the effectiveness of the drug recall system. Now our company starts the (simulated) recall work according to the "Measures for the Administration of Drug Recall".
2023-07-10
10
2023-07
Good news! Good news! Good news!
When the spring of 2023 is approaching, Anhui Pioneer Pharmaceutical Co., Ltd. received the great news that fenofibrate capsules (specification: 0.2g) obtained the consistency evaluation approval.
2023-07-10
Contact us
Add：No.35 HongFeng Road, Hefei, Anhui, China.
Tel：86-551-65355028
Fax：86-551-65355022
Email：xfcn@xfcn.com
Follow us
Copyright © 2023 Anhui Pioneer Pharmaceutical Co., Ltd 皖ICP备2020016893号 Powered by：www.300.cn SEO
86-551-65355028